Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status. by Gyaase, Stephaney et al.
RESEARCH ARTICLE Open Access
Potential effect modification of RTS,S/AS01
malaria vaccine efficacy by household
socio-economic status
Stephaney Gyaase1, Kwaku Poku Asante1,2, Elisha Adeniji1, Owusu Boahen1, Matthew Cairns2 and
Seth Owusu-Agyei1,2,3*
Abstract
Background: In the phase III RTS,S /AS01 trial, significant heterogeneity in efficacy of the vaccine across study sites
was seen. Question on whether variations in socio - economic status (SES) of participant contributed to the
heterogeinity of the vaccine efficacy (VE) remains unknown.
Methods: Data from the Phase III RTS,S /AS01 trial in children aged 5–17 months in Kintampo were re-analysed. SES
of each child was derived from the Kintampo Health and Demographic Surveillance System, using principal
component analysis of household assets. Extended Cox regression was used to estimate the interaction between
RTS,S/AS01 VE and household SES.
Results: Protective efficacy of the RTS,S/AS0 vaccine significantly varied by participant’s household SES, thus
increase in household SES was associated with an increase in protective efficacy (P-value = 0.0041). Effect
modification persisted after adjusting for age at first vaccination, gender, distance from community to the health
facility, child’s haemoglobin level, household size, place of residence and mothers’ educational level.
Conclusion: Household SES may be a proxy for malaria transmission intensity. The study showed a significant
modification of the RTS,S/AS01 malaria vaccine efficacy by the different levels of child’s household socio - economic
status.
Trial registration: Efficacy of GSK Biologicals’ candidate malaria vaccine (25049) against malaria disease in infants
and children in Africa. NCT00866619 prospectively registered on 20 March 2009.
Keywords: Socio-economic status, Malaria, Vaccine, Protective efficacy, Malaria incidence
Background
Significant attempts have been made to address the bur-
den of malaria in endemic countries. Despite signs of
substantial global progress, the burden in some develop-
ing countries remains high, resulting in a negative im-
pact on health and livelihoods. Ghana remains one of
the countries in Africa with the highest burden of mal-
aria, with a reported increase in malaria cases in 2018
compared to 2017. Malaria accounted for close to 34%
of total outpatients’ cases, 55.6% of all admissions and
54.6% of deaths in children who were under 5 years of
age. Plasmodium falciparum remains the most prevalent
malaria parasite in Ghana and reflects the sub–Saharan
Africa endemicity, where it accounted for over 99% of
malaria cases in 2018 among young children [1–3].
The RTS,S /AS01 malaria vaccine (Mosquirix) has
been developed as an additional tool for malaria control.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: sowusuagyei@uhas.edu.gh
1Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
2Tropical Epidemiology Group, London School of Hygiene and Tropical
Medicine, London, UK
Full list of author information is available at the end of the article
Gyaase et al. BMC Public Health          (2021) 21:240 
https://doi.org/10.1186/s12889-021-10294-x
In the pivotal phase III RTS,S /AS01 malaria vaccine
trial, the incidence rate for all episodes of clinical mal-
aria was 0.69/person-years in the RTS,S /AS01 group
and 1.17/person-years in the control group in the per-
protocol population based analysis on the primary case
definition after 18 months follow-up. This resulted in a
protective efficacy of 46% (95% CI: 42, 50%) against clin-
ical malaria in children aged 5 to 17 months. Within the
same age group, the incidence rate of clinical malaria
based on the per-protocol definition for the Kintampo
Health Research site was 1.01/person-years and 1.85/
person-years in the RTS,S/AS01 and control groups re-
spectively. This resulted in the protective efficacy of 47%
(95% CI: 39.1, 54.2%) for the research site.
However, significant heterogeneity in vaccine efficacy
ranging from 40 to 77% (interaction test, p, 0.001) was
observed across study sites [4]. The reported heterogen-
eity in VE was investigated using malaria transmission
intensity defined as the occurrence of clinical malaria
within the control group at a given site. The heterogen-
eity of the vaccine efficacy across study sites and it being
shown to be higher at low transmission areas and lower
at higher transmission areas [4] suggest that, occurance
of clinical malaria alone could not have accounted for
this heterogeneity but other factors such as receipent’s
socio-economic status could have influenced the results
of the trial. Other research findings have showed the
modification of one’s socio - economic status and efficacy
of vaccines. A study by Gosselin et al. showed that SES
seemed to have influence on the efficacy of rotavirus vac-
cine. Children living with high rates of low-income fam-
ilies was shown to have had a significant lower VE
compared to children living with lower rates of low-
income families [5]. Again, Lopman et al. also showed that
rotavirus vaccine prevented gastroenteristics diseases by
93, 86 and 51% in high, middle and low SES repectively
[6]. Also, findings of a population-based case-control co-
hort analysis by Hammer et al. during the pertussis out-
break in 2004/2005 also found the effectiveness of the
pertussis vaccine being influenced by SES [7]. Though the
RTS,S/AS01 Phase III clinical trial was conducted in a
standardized clinical and laboratory methods across study
sites, the critical question of whether variations in socio -
economic status of participant contributed to the hetero-
geinity of the RTS,S/AS01 VE remains unknown [4].
Kintampo Health reasrch centre which was part of the
Phase III clinical trial is a peri-urban with malaria trans-
mission being high, with seasonal peaks and troughs [8].
Again, individual household socio-economic indicators
in this study site have also been showed to be an indica-
tor for malaria exposure, thus malaria exposure being
low for high SES and high for low SES [9]. This makes
the study site ideal to examine the modification of SES
on the RTS,S/AS01 VE.
The objective of the study was to invitigate the vari-
ability of the RTS,S/AS01 malaria vaccine, using SES as
a proxy for malaria exposure in the Kintampo site in
Ghana.
A description of the demographic characteristics and
the incidence of clinical malaria episodes are described
in the results section. We discussed and conclude that,
Socioeconomic status was an effect modify of the RTS,S/
AS01 malaria vaccine efficacy.
Methods
Data
The methods and results of the original phase III RTS,S
/AS01 clinical trial and this study have been reported ac-
cording to CONSORT guidelines [10] . Data for this re-
search was obtained from the Phase III RTS,S /AS01
malaria vaccine trial (NCT00866619) involving children
aged 5–17 months. The children were enrolled in the
Kintampo Health Research Centre study area located in
the Kintampo North Municipality and Kintampo South
District in the Bono-East Region of Ghana. This study
area has been endowed with a Health and Demographic
Surveillance System (HDSS) that collects socio-
demographic data on the population. The total surface
area of these two districts is 7162 km2 and comprises of
about 156,145 residents (Kintampo Health Research An-
nual Report, 2016).
The methods deployed in the main trial have been
published elsewhere [11]. In summary, the trial was a
randomised, double-blind controlled trial of the candi-
date RTS,S/AS01 malaria vaccine, conducted at 11 sites
in seven sub-Sahara African countries with varied mal-
aria transmission. The trial was designed to evaluate
malaria vaccine efficacy, safety and immunogenicity in
infants and young children. A randomisation ratio of 1:1:
1 was used with the first group receiving three doses of
the RTS,S/AS01 at monthly intervals, followed by a
booster dose at 18 months after completing the primary
vaccinations; the second group received the RTS,S
/AS01 primary vaccination series without the booster
and the third group received comparator vaccines.
For this analysis, data from children in the first and
second groups, that is all children who received at least
one dose of RTS,S/AS01 malaria vaccine, were combined
and compared with the third group (control group) in
the ratio of 2:1. A clinical malaria episode was defined
based on a participant presenting at the health facility
with axillary temperature ≥ 37.5 °C and presence of Plas-
modium falciparum asexual parasitaemia greater than
zero parasites/μL. To avoid counting the same episode
more than once, any episode of clinical malaria docu-
mented within 14 days of treatment for a previous epi-
sode was discounted. A total of 1002 children who were
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followed up to 18 months after completing the primary
vaccination series was included in the analysis.
Data on household SES of each participating child was
obtained from the Kintampo Health and Demographic
Surveillance System (KHDSS). The KDDSS process in-
volved administering a standardised SES questionnaire
to each household head or in their absence, an adult
resident member of the household who was present on
the day of the interview. All respondents were ques-
tioned about ownership of household assets including
television, radio, bicycle, motorcycle, refrigerator, car,
ownership of farmland, electricity at homes. Other SES
variables that they enquired about included the type of
building material, ceiling in the house, room floor cover,
number of sleeping rooms, home ownership, source of
drinking water, type of toilet facility and household own-
ership of domestic animals such as poultry, goat, sheep,
pigs, cattle among others.
Statistical methods
In this analysis, SES was assessed using household assets
(ownership of television, radio, motorcycle, refrigerator,
car, farmland, mattress, internet, satellite disc, electricity
at home, type of material used for roofing, building ma-
terial used for room floor and walls, source of water, toi-
let facility and ownership of domestic animals such as
pigs, sheep among others). Both categorical and continu-
ous data were collected during interviews on household
assets. Questions based on these household assets were
used in generating assets scores for each household. An
overall wealth index was computed for each participant,
using principal component analysis (PCA) as described
by Vyas et al. [12]. The first component was used in gen-
erating household wealth index. Participants were
grouped by wealth index that is based on their SES, with
tertiles used to classify a child’s SES as low, medium or
high.
Incidence of clinical malaria was estimated as the total
number of clinical malaria episodes experienced by each
child after the primary vaccination series and until 18
months post-vaccination follow-up. An extended Cox
regression model [13] was used to estimate the hazard
ratio comparing RTS,S/AS01 recipients with the control
groups. Vaccine efficacy was estimated as one minus the
hazard ratio, expressed as a percentage. The primary
comparison of interest was the interaction between the
study group and household socio-economic status, with
the Wald test of the interaction parameter used to assess
the evidence against the null hypothesis of no
interaction.
A set of variables: haemoglobin status, classified into
< 10 g/dL as anaemic and ≥ 10 g/dL as normal; distance
between the resident community of a participant and
the nearest health facility based on the road networks,
classified into < 5 km, 5-10 km, 11-15 km and above 15
km; place of residence, classified as either rural or urban;
household (HH) size, classified as < 5 persons per HH or
above 5 persons per HH; age group at first vaccination,
classified as 5–8 months, 9–12 months, 13–17months;
care giver’s educational level, classified as none, primary,
secondary or higher and gender of the respondent.
These were considered as potential confounders for in-
clusion in the final model.
Vaccine-preventable disease incidence (VPDI) for each
SES level was estimated based on a weighted least-squares
regression model with robust standard error [14].
The analysis was carried out using STATA 14 (Stata-
Corp, TX, USA) and R version 3.5.0.
Results
Study participants
Of the 1002 children included in this analysis, 668 were
assigned to the RTS,S/AS01 malaria vaccine group and
334 to the control group. Males constituted 51.4% of the
total participant’s data analysed. Majority of the children
were within the ages thirteen and seventeen months
when they were enrolled at vaccination. Distribution of
the different levels of SES was similar between the two
groups; ten of the participants, however, did not have in-
formation on their socio-economic status (Table 1).
Descriptive statistics of other demographic factors by
household socio - economic status
More than half of the children classified within the
medium and low SES had caregivers with no basic
school education (that is no formal education), com-
pared to the majority of children classified within the
high SES who had caregivers with secondary or higher
education. The number of persons per household was
evenly distributed between less than five and above five
persons per household. Majority of households in the
rural communities were those with low SES, compared
to those with high SES who were more frequently from
urban communities. More than half of the children from
the low and medium SES were anaemic, compared to
the other half of children within the high SES with nor-
mal haemoglobin levels. About 5% of the participants
care givers information on educational status were miss-
ing. Again, there were no information on place of resi-
dence for about 7% of the participants in the study
(Table 2).
Majority of participants in households with high socio-
economic status lived closer to a health facility com-
pared to the majority of the participants from house-
holds with low SES who lived more than 10 km away
from a health facility (Fig. 1).
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Malaria incidence by household SES group
A total of 2651 distinct episodes of clinical malaria
were recorded over the 18 months’ period of follow-
up. Overall, 1464 episodes were recorded in 828.41
person-years for the 668 children in the RTS,S/AS01
group and 1187 episodes in 399.76 person-years for
the 334 children in the control group. The incidence
rate ratio (IRR) of clinical malaria in the study was
0.58 (95% CI: 0.52, 0.66) and the protective efficacy
was estimated as 42% (95% CI: 0.34, 0.48)].
For both treatment group, there were 1153 distinct ep-
isodes of clinical malaria in 410.13 person-years, 914 dis-
tinct episodes of clinical malaria in 415.00 person-years
and 558 distinct episodes of clinical malaria in 391.65
person-years experienced by children from the house-
hold with low, medium and high socio-economic status
respectively. In the intervention group, the incidence
rates of clinical malaria for the low, medium and high
SES were 2.40 (95% CI: 2.22, 2.59), 1.88 (95% CI: 1.73,
2.05) and 0.97 (95% CI: 0.86, 1.09) per child years at risk
respectively. In the control group, the corresponding in-
cidence rates of clinical malaria for each level of SES
were 3.67 (95% CI: 3.3, 4.00), 2.89 (95% CI: 2.62, 3.20)
and 2.37 (95% CI: 2.12, 2.65) (Table 3).
The rate of clinical malaria kept increasing over the
follow-up period, though the increase was higher for
children in the control group compared to the RTS,S/
AS01 group. However, the rate of clinical malaria for
children from high SES in the control group and chil-
dren from low SES in the RTS,S/AS01 group seemed
similar over time (Fig. 2).
Though the protective efficacy of the RTS,S /AS01
malaria vaccine for children in the low (VE = 36, 95% CI:
25, 45%) and medium SES class (VE = 36, 95% CI: 22,
47%) were similar, the protective efficacy was about
twice as high among children in the high SES group
(VE = 61, 95% CI: 49, 70%). There was strong evidence
for effect modification, (p = 0.0041).
The vaccine-preventable disease incidence over 18
months of follow-up in the three different SES groups
was 1268.5, 1015.3 and 1401.8 per 1000 children vacci-
nated for children from the low, medium and high SES
respectively. The low vaccine efficacy in the group with
the highest incidence (low SES) and the highest vaccine
efficacy in the group with the lowest malaria incidence
(high SES) resulted in similar VPDI in these two groups.
Table 1 Comparing participants basic demographics status between the groups
Attribute RTS,S /AS01 Group (N = 668)
% (n)
Control Group (N = 334)
% (n)
Age at Vaccination
5–8 months 26.7 (178) 23.7 (79)
9–12 months 20.8 (139) 25.7 (86)
13–17months 52.5 (351) 50.6 (169)
Gender
Male 53.6 (358) 47.0 (157)
Female 46.4 (310) 53.0 (177)
Socio - Economic Status
Low 33.8 (226) 33.8 (113)
Medium 34.4 (230) 32.0 (107)
High 31.0 (207) 32.6 (109)
Missing 0.7 (5) 1.5 (5)
Table 2 Summary statistics of participant basic demographics











Care Giver’s educational status
None 64.3 (218) 50.4 (170) 34.5 (109)
Primary 12.1 (41) 19.0 (64) 18.7 (59)
Secondary / Higher 13.6 (46) 20.8 (70) 43.0 (136)
Missing 10.0 (34) 9.8 (33) 3.8 (12)
Household Size
Above 5 person/HH 48.7 (165) 50.7 (171) 42.4 (134)
Less than 5 person/HH 51.3 (174) 49.3 (166) 57.6 (182)
Place of Residence
Rural 80.5 (273) 64.7 (218) 39.9 (126)
Urban 14.4 (49) 28.2 (95) 50.0 (158)
Missing 5.0 (17) 7.1 (24) 10.1 (32)
Haemoglobin Status (Child)
Normal 34.2 (116) 41.2 (139) 51.3 (162)
Anaemic 65.8 (223) 58.8 (198) 48.7 (154)
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After adjusting for distances from communities to the
health facility, child’s haemoglobin level, gender of the
child, household size, place of residence and mother’s
educational level, age at first vaccination, the efficacy of
the vaccine still varied with SES, (p = 0.0029). The pro-
tective efficacy still decreased as the child’s SES de-
creased. Again, the efficacy of the vaccine for children
from the high SES was about twice the efficacy of the
vaccine for children from the low SES (Table 4).
Twenty-two percent (217) of children in the entire co-
hort did not experience any clinical malaria episodes
throughout the 18-month follow-up period. For children
without clinical malaria episodes throughout the 18-
month follow-up period, 80.6% (175) were in the inter-
vention group whiles 19.3% (42) were in the control
group.
Discussion
In this study, we explored the potential interactions be-
tween RTS,S/AS01 vaccine efficacy and household
socio-economic status. In the pivotal Phase III clinical
trial, VE was seen to be homogeneous across site. Albeit,
this homogeneity was not explained by transmission, the
study found the efficacy of the vaccine to be higher in
areas with low clinical malaria incidence. Similarly, stud-
ies have shown that clinical malaria incidence is low for
households with high SES compared to household with
low SES within the Kintampo health research study area
[4, 9]. SES was therefore treated as a proxy for malaria
transmission intensity to explore the potential inter-
action with malaria RTS,S/AS01 vaccine.
VE against clinical malaria was seen to have a signifi-
cant heterogeneity among the different study participant
groups. This heterogeneity was, however, seen to be
driven by the participant’s household socio-economic
status; individuals of higher socio-economic status expe-
rienced markedly lower malaria incidence rates. Thus,
VE was higher among SES group with lower exposure
resulting in better protection.
This study finding, demonstrating that RTS,S /AS01
malaria vaccine efficacy varies according to the socio-
economic status of the recipient, is consistent with the
Fig. 1 Description of distance/km travelled by paticipants from the community to the nearest health facility in the study area
Table 3 Comparing the incidence of clinical malaria among the treatment groups





Person time at Risks
(years)
Rate 95% CI Total
Episode
Person time at Risks
(years)
Rate 95% CI
Low 663 276.48 2.40 2.22–
2.59
490 133.64 3.67 3.35–
4.00
Medium 533 283.43 1.88 1.73–
2.05
381 131.57 2.89 2.62–
3.20
High 256 264.26 0.97 0.86–
1.09
302 127.39 2.37 2.12–
2.65
Missing 12 4.23 2.8 1.61–
4.99
14 7.15 1.96 1.16–
3.30
Rate is Episodes of clinical malaria per person-years at risk
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broad patterns observed in the Phase III RTS,S/AS01
trial. In that study, VE was higher in low malaria trans-
mission settings than in higher malaria transmission set-
tings [4]. Again the findings in this study are in line with
the Phase 2 trials, which also found the efficacy of the
RTS,S/AS01 malaria vaccine decreasing with increasing
exposure [3]. In the present study, individuals of high
SES, who were at much lower overall risk of malaria, ex-
perienced markedly higher vaccine efficacy. The result is
also consistent with other research findings, which found
a positive association of other vaccines and one’s socio-
economic status [5–7, 15]. One of these studies by Lop-
man et al. was on children aged between 6 and 23
months, demonstrated that rotavirus vaccine prevented
93, 86 and 51% of severe rotavirus gastroenteritis in
high, middle and low SES respectively [6]. Another study
carried out in Quebec using the rotavirus vaccine among
children less than 3 years of age also found children
from a neighbourhood with a higher rate of low-income
families having a significantly low VE compared to
children from a neighbourhood with a lower rate of low-
income families (30% vs. 78%, p = 0.027) [5]. A study
that investigated the effectiveness of new group B strain-
specific meningococcal vaccine in New Zealand also
found significantly higher meningococcal rates for higher
levels of deprivation (p < 0.001) [15]. Furthermore, a
study that investigated Pertussis vaccine found the vac-
cine to be 79, 86, 83 and 94% for children in the first,
second, third and fourth quartiles of houses (an indica-
tor of SES) respectively (p = 0.03) [7].
Reasons that might contribute to the low efficacy
among low SES include housing quality, level of expos-
ure, reduction in vaccine immunogenicity, infectious
agent, one’s susceptibility to agent among others. Poor
households are likely to live in rural areas with poor
housing quality, poor sanitation and high malaria breed-
ing sites that will lead to a higher risk of transmission [9,
16–18]. In this study, more than half of the population
with low or medium socio-economic status reside in the
rural parts of the study area, in houses built with mud
Fig. 2 Cumulative hazard of the effect of child’s HH SES on the RTS,S /AS01 malaria vaccine efficacy over the follow-up period
Table 4 Incidence rate ratio of clinical malaria for each SES stratum
Parameter Unadjusted Adjusted
Protective Efficacy (Percent) 95% CI P-Value Protective Efficacy (Percent) 95% CI P-Value
Low SES 35.65 25.04–44.76 < 0.001 32.64 21.75–42.01 < 0.001
Medium SES 35.75 22.28–46.89 < 0.001 36.11 22.89–47.06 < 0.001
High SES 60.83 48.79–70.03 < 0.001 60.01 47.94–69.29 < 0.001
Wald test and P-value for an interaction effect between participant’s SES and the treatment groups for the unadjusted model was (χ2 = 10.99, P-value = 0.0041)
and was (χ2 = 11.74, P-value = 0.0028) for the adjusted model
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and straw roofing that create easy access routes for in-
fective malaria mosquitoes. Their homes are usually lo-
cated in areas with unkept bushes, no proper drainage
and without designated places for waste disposal. All
these facilitate congenial environments for breeding mal-
aria mosquitoes [9, 16–18].
Distances from rural communities to health facilities
have been associated with the risk of malaria infection in
places with high malaria transmission [19]. Those living
far from health facilities find it more difficult in acces-
sing the health-care facility. Majority of participants in
this study who were within the low SES households lived
far from health facilities with poor access to the main
facility.
Though SES could be a malaria-risk factor that modi-
fies VE, other biological factors including immune re-
sponses could also explain the lower VE among
participants of low SES. Low haemoglobin has been re-
ported to be associated with poor immune responses
[20, 21]; Our study findings document a higher propor-
tion of participants, i.e. more than half of the children
from the low SES had low haemoglobin.
To ascertain whether the interactive effect between
RTS,S/AS01 malaria vaccine efficacy and caregiver’s
household SES was real rather than spurious, the model
adjusted for the gender of the child, caregiver’s educa-
tional status, distance from the household to a health fa-
cility, the size of the household, haemoglobin status of
the child, place of residence, age at first vaccination. The
interaction effect remained statistically significant.
There are, however, some caveats to this finding. First,
this study uses SES as a proxy to a true measure of ex-
posure given that direct measurements, such as entomo-
logical inoculations are expensive and imprecise due to
the microheterogeneity of malaria transmission [22].
Again, 0.9% of the participants did not have SES infor-
mation and were therefore not eligible for inclusion in
the analysis. Excluding them from the analysis did not
bias the results as their exclusion did not alter the distri-
bution of SES categories between the RTS,S/AS01 and
control group. Other residual confounding could have
resulted from variables used in the SES estimation but
these were not measured.
Conclusion
This study showed a significant modification of the RTS,
S/AS01 malaria vaccine efficacy by the different levels of
child’s household socio-economic status. The effect of
the modification remained statistically significant after
adjusting for other potential confounders.
This study suggests that the impact of the RTS,S/AS01
malaria vaccine may be minimal in groups that most
need it and that other measures to ensure clinical
malaria incidence remains low will be of great public
health importance.
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